Moleculin Reports Third Quarter 2022 Financial Results and Provides Pipeline Update

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug...

Related Keywords

Houston ,Texas ,United States ,Poland ,United Kingdom ,Warsaw ,L67 ,Jenene Thomas ,Tacaribe Arenavirus ,Walter Klemp ,Piotr Rutkowski ,Moleculin Biotech Inc ,Company Phase ,Linkedin ,Maria Sklodowska Curie National Research Institute Of Oncology ,Emory University ,Twitter ,National Institute Of Allergy ,National Institutes Of Health ,Drug Administration ,Nasdaq ,Exchange Commission ,European Medicines Agency ,Facebook ,Securities Exchange ,Prnewswire Moleculin Biotech Inc ,Three Phase ,Chief Executive Officer ,Acute Myeloid Leukemia ,National Institute ,Infectious Diseases ,National Institutes ,Orphan Drug Designation ,Glioblastoma Multiforme ,Generation Anthracycline ,Bone Sarcoma ,Fast Track Status ,Orphan Drug ,Fast Track Designation ,Acute Myeloid ,Report Phase ,Transcription Modulator ,Regulatoryt Cells ,Rare Pediatric Disease ,Glycosylation Inhibitor ,Investigational New Drug ,Financial Results ,Third Quarter ,Moleculin Biotech Conference ,Moleculin Biotech ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Condensed Consolidated Statements ,Months Ended September ,Nc ,